

4-(1,3-Benzodioxol-5-yl)-2-oxo-1,2,5,6-tetrahydrobenzo[*h*]quinoline-3-carbo-nitrile

Abdullah M. Asiri,^a Hassan M. Faidallah,^a
Abdulrahman O. Al-Youbi,^a Khalid A. Alamry^a and
Seik Weng Ng^{b,a*}

^aChemistry Department, Faculty of Science, King Abdulaziz University, PO Box 80203 Jeddah, Saudi Arabia, and ^bDepartment of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia

Correspondence e-mail: seikweng@um.edu.my


Received 7 August 2011; accepted 19 August 2011

Key indicators: single-crystal X-ray study; $T = 100$ K; mean $\sigma(\text{C}-\text{C}) = 0.002$ Å; R factor = 0.036; wR factor = 0.100; data-to-parameter ratio = 13.6.

In the molecule of the title compound, $C_{21}H_{14}N_2O_3$, the tetrahydrobenzo[*h*]quinoline fused-ring system is buckled owing to the ethylene $-\text{CH}_2\text{CH}_2-$ fragment, the benzene ring and the pyridine ring being twisted by $24.3(1)^\circ$. The ring of the benzodioxol system is bent away from the pyridine ring by $61.4(1)^\circ$ in order to avoid crowding the cyanide substituent. Two molecules are linked by a pair of $\text{N}-\text{H}\cdots\text{O}$ hydrogen bonds to form a centrosymmetric dimer.

Related literature

For background to the anticancer properties of this class of compounds, see: Rostom *et al.* (2011).



Experimental

Crystal data

| | |
|----------------------------|-----------------------------------|
| $C_{21}H_{14}N_2O_3$ | $V = 1640.77(11)$ Å ³ |
| $M_r = 342.34$ | $Z = 4$ |
| Monoclinic, $P2_1/n$ | $\text{Cu } K\alpha$ radiation |
| $a = 7.6586(3)$ Å | $\mu = 0.77$ mm ⁻¹ |
| $b = 16.5858(5)$ Å | $T = 100$ K |
| $c = 13.3220(6)$ Å | $0.30 \times 0.20 \times 0.05$ mm |
| $\beta = 104.164(4)^\circ$ | |

Data collection

| | |
|--|--|
| Agilent SuperNova Dual diffractometer with Atlas detector | 6078 measured reflections |
| Absorption correction: multi-scan (<i>CrysAlis PRO</i> ; Agilent, 2010) | 3241 independent reflections |
| $T_{\min} = 0.802$, $T_{\max} = 0.963$ | 2962 reflections with $I > 2\sigma(I)$ |
| | $R_{\text{int}} = 0.014$ |
| | |

Refinement

| | |
|---------------------------------|--|
| $R[F^2 > 2\sigma(F^2)] = 0.036$ | H atoms treated by a mixture of independent and constrained refinement |
| $wR(F^2) = 0.100$ | $\Delta\rho_{\text{max}} = 0.21$ e Å ⁻³ |
| $S = 1.02$ | $\Delta\rho_{\text{min}} = -0.22$ e Å ⁻³ |
| 3241 reflections | |
| 239 parameters | |

Table 1
Hydrogen-bond geometry (Å, °).

| $D-\text{H}\cdots A$ | $D-\text{H}$ | $\text{H}\cdots A$ | $D\cdots A$ | $D-\text{H}\cdots A$ |
|---|--------------|--------------------|-------------|----------------------|
| N1—H1···O1 ⁱ | 0.93 (2) | 1.85 (2) | 2.778 (1) | 175 (2) |
| Symmetry code: (i) $-x + 1$, $-y + 1$, $-z + 1$. | | | | |

Data collection: *CrysAlis PRO* (Agilent, 2010); cell refinement: *CrysAlis PRO*; data reduction: *CrysAlis PRO*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 2008); program(s) used to refine structure: *SHELXL97* (Sheldrick, 2008); molecular graphics: *X-SEED* (Barbour, 2001); software used to prepare material for publication: *publCIF* (Westrip, 2010).

The authors thank King Abdulaziz University and the University of Malaya for supporting this study.

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: XU5293).

References

- Agilent (2010). *CrysAlis PRO*. Agilent Technologies, Yarnton, Oxfordshire, England.
- Barbour, L. J. (2001). *J. Supramol. Chem.* **1**, 189–191.
- Rostom, S. A. F., Faidallah, H. M. & Al-Saadi, M. S. (2011). *Med. Chem. Res.* **20** (DOI: 10.1007/s00044-010-9469-0).
- Sheldrick, G. M. (2008). *Acta Cryst. A* **64**, 112–122.
- Westrip, S. P. (2010). *J. Appl. Cryst.* **43**, 920–925.